Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.53 |
| ▸ | GRM3 | Q14832 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | GRM8 | O00222 | 2/20 | 0.53 |
| ▸ | GRM6 | O15303 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.53 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601083 | 0.88 | GRM4 (0.47) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4601909 | 0.88 | GRM4 (0.47) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL11919493 | 0.74 | FFAR3 (0.44) | CYP2C19TDP1LMNAMTORALDH1A1 | |
| SCHEMBL25492415 | 0.74 | GRM4 (0.59) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2898361 | 0.74 | GRM4 (0.59) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL8532181 | 0.74 | GRM4 (0.59) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL5049246 | 0.72 | GRM4 (0.47) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL29952939 | 0.71 | GRM4 (0.61) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2657478 | 0.71 | EPHX1 (0.37) | CYP1A2CYP2C19TDP1LMNAMTOR | |
| SCHEMBL29952657 | 0.71 | GRM4 (0.61) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| EP-2245012-B1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | c/o Chroma Therapeutics Ltd. (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | GRM4 240/4885GRM2 125/4885GRM3 87/4885 |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MAPK3, MAPK1, MAPKAPK3 | GRM4 3252/4885GRM2 2152/4885GRM3 716/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | GRM4 240/4885GRM2 125/4885GRM3 87/4885 |
| US-20100317865-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | GRM4 240/4885GRM2 125/4885GRM3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.